Anoop M. Nambiar

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

Jamie N. Justice, Anoop M. Nambiar, Tamar Tchkonia et al. · EBioMedicine · 2019 · 1.2K citations · Full text

Education, Pharmacotherapy, Aging +15

Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection

Tanayott Thaweethai, Sarah E. Jolley, Elizabeth W. Karlson et al. · JAMA · 2023 · 848 citations · Full text

Veterinary Medicine, Infectious Diseases, Clinical Epidemiology +14

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

Anoop M. Nambiar, Dean L. Kellogg, Jaime Justice et al. · EBioMedicine · 2023 · 256 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Pulmonary function measures predict mortality differently in IPF <i>versus</i> combined pulmonary fibrosis and emphysema

S. Schmidt, Anoop M. Nambiar, Nabihah Tayob et al. · European Respiratory Journal · 2010 · 166 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17